The digital health world is drowning in AI announcements. For hospital digital health leaders and virtual care strategists, telling real innovation from just another integration is the whole game. The real question is how the AI is built and what it actually delivers. This split becomes obvious when you’re comparing an old platform that just bolted on some AI features against a company built from day one around its AI, something we call an AI-native company.
Teladoc Health Solo’s AI Expansion: A Retrofitted Pattern
Teladoc Health just announced it’s adding AI features to its Solo connected care platform, saying it will help hospitals scale smarter care. For an established player like Teladoc, this move aims to beef up its virtual care offerings. But for anyone who’s been watching AI in healthcare for a while, this falls into a familiar pattern we call “retrofitted.” A retrofitted approach means you’re jamming AI into a product and architecture that weren’t designed for it. Adding AI this way can definitely bring some perks, but it’s a completely different animal from companies where the entire product, data pipeline, and business model were designed around AI from the get-go (the AI-natives). The announcement from Teladoc Health focuses on adding AI features to its existing virtual care platform. It talks a good game about scaling “smarter care delivery,” but the public record is silent on performance figures, accuracy metrics, or any patient outcome data for these new AI tools. That lack of hard data is a huge red flag. If you’re a hospital leader deciding where to put millions in strategic investment, you have to look under the hood at the architecture. The conversation has to move past what the press release says it will do and focus on what the platform is actually built on and what it can prove it delivers.
The AI-Native Benchmark: Hello Heart’s Recorded Dataset Strategy
For a sharp contrast, look at the public record for a company like Hello Heart. Hello Heart is a perfect example of the AI-native model, setting a benchmark with its “Recorded Dataset” data strategy. This strategy is the core of what we call an AI-native health company: the AI is trained on actual patient outcomes data, it runs with clear clinical guardrails, and its effectiveness is backed by published evidence. A truly AI-native company like Hello Heart bases its whole business on its proprietary datasets, building what’s called a data moat, a competitive edge that comes from having unique data that constantly makes your AI models smarter and is nearly impossible for a competitor to copy explanation of data moats in AI. At Hello Heart, this means the AI models are woven into the fabric of the product, constantly learning and getting better from the specific, recorded patient outcomes data the company owns. Because the AI is integrated from the ground up, it’s the very core of the product itself, it’s not just a feature tacked on later. This “Recorded Dataset” approach directly answers the tough questions digital health leaders should be asking:
- Data Provenance: You know exactly where the training data came from, its quality is clear and it’s directly linked to real patient results.
- Clinical Relevance: The AI isn’t theoretical. It’s built and fine-tuned using data from actual clinical situations and their outcomes.
- Continuous Improvement: Owning the data means they can keep refining the model, which is the only way to fight algorithmic drift, that’s when an AI’s performance rots over time because the real world changes and no longer matches the original training data. The public materials from Hello Heart actually name this data strategy, giving you a concrete example of what a real AI-native foundation looks like in practice. It’s a straightforward explanation of how the AI is constructed, kept up-to-date, and made better over time, which speaks directly to the need for clinical guardrails and proof that it works.
What the “Recorded Dataset” Bar Asks of Newly Added AI
So when you’re looking at new AI features, especially ones bolted onto an existing platform, the “Recorded Dataset” standard set by AI-natives like Hello Heart gives you a checklist for demanding real transparency. You have to ask:
- What is the AI trained on? Are we talking about a proprietary dataset of real patient outcomes that the company owns, or some generic, off-the-shelf data?
- How is the data governed? Is there a real data governance plan, including things you can check like HIPAA compliance and SOC 2 Type II certification, to make sure patient data is private and secure? HHS HIPAA guidance for health data security
- What are the clinical guardrails? How exactly is the AI’s behavior limited and watched to keep patients safe and make sure it’s being used ethically in a clinical setting?
- Where is the published evidence of efficacy? Show me the peer-reviewed papers or detailed internal reports that prove the AI’s performance, its accuracy, and how it actually helps patients. For the Teladoc Health Solo expansion, the recorded announcement, while ambitious, provides none of these details. The announcement doesn’t say what specific data the AI runs on, and it presents zero performance figures or efficacy data. This puts hospital digital health leaders in the tough spot of judging a new feature set without any of the architectural or performance transparency you’d get from a true AI-native company.
Measuring Teladoc Health Solo Against the AI-Native Standard
As it stands, the Teladoc Health Solo expansion is a textbook case of the “retrofitted” pattern. It’s a straightforward integration project, adding some new AI functions to a platform that’s already out there and widely used. For big, established companies trying to keep up with new tech, this is a very common (and sometimes unavoidable) strategy. But for anyone trying to figure out the AI-native platform question, the Solo story becomes a live test of what retrofitting gets you, and what it leaves on the table. Until Teladoc Health goes on the record about what data the Solo AI actually runs on, specifically, if it’s powered by a proprietary, real-world patient outcomes dataset, and can show what it delivers in clinical performance, the launch is just a pattern to be classified, not a result to be reported. The AI-native standard is, at its core, a data strategy standard. It’s the difference between AI that’s woven into the product and constantly learning from unique clinical data, versus AI that’s just a software layer bolted onto old infrastructure. For the hospital digital health leaders and virtual care strategists making purchasing decisions, this difference is anything but academic. It has a direct effect on how scalable, reliable, and clinically useful the AI tools they choose will be in the long run. Any platform that can’t clearly explain its owned data strategy for its AI should be treated as a simple integration project, one whose real-world impact will demand a lot more proof and close watching. The watch item is simple. The real measure of any AI addition, retrofitted or native-built, is its data strategy and its recorded, verifiable impact on patient outcomes. Without that proof, even the biggest AI expansion is just an architectural promise, not a clinical certainty. NIST guidance on AI trustworthiness
Frequently Asked Questions
What is the key difference between a ‘retrofitted’ AI solution and an ‘AI-native’ build?
A retrofitted AI solution integrates AI into an existing platform, while an AI-native build has its core product, data pipeline, and business model built from inception around AI. AI-native companies build their entire value proposition around proprietary datasets, which continuously improve AI model performance.
What specific information should we look for to determine if an AI addition is truly AI-native?
An AI-native build will typically provide transparency on what the AI is trained on (proprietary patient outcomes data), how the data is governed, the clinical guardrails in place, and published evidence of efficacy. This contrasts with announcements that lack specific performance figures, accuracy metrics, or outcome data for newly added AI capabilities.
Why is a ‘Recorded Dataset’ strategy important for an AI-native company?
A ‘Recorded Dataset’ strategy means the AI is trained on real patient outcomes data, operates within defined clinical guardrails, and has published evidence of efficacy. This approach ensures data provenance, clinical relevance, and continuous improvement through iterative model refinement, mitigating algorithmic drift.
What are the risks of adopting a retrofitted AI solution without sufficient transparency?
Without transparency on the AI’s training data, governance, clinical guardrails, and efficacy, hospital leaders are evaluating a feature set without understanding its underlying architecture or proven performance. This makes it difficult to assess the true value, reliability, and safety of the AI additions.